Canada markets open in 7 hours 28 minutes

Neovasc Inc. (NVCN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
9.40-0.80 (-7.84%)
At close: 03:59PM EDT
Full screen
Previous Close10.20
Open9.65
Bid9.40 x 0
Ask9.63 x 0
Day's Range9.40 - 9.84
52 Week Range6.00 - 27.00
Volume1,419
Avg. Volume506
Market Cap25.654M
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)-15.77
Earnings DateAug 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Neovasc to Report Second Quarter Financial Results on August 11, 2022

    Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.Interested parties may access the conference call by dialing ...

  • GlobeNewswire

    Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

    VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mecha

  • Baystreet

    Stocks in play: Neovasc Inc

    Today announced that the company has expanded its direct sales operations in Europe to include the United ...